Journal of International Psychiatry

Abstract: Objective: To explore the improvement effect of citalopram adjuvant therapy on negative emotions and quality of life in patients with chronic obstructive pulmonary disease (COPD). Method: Case data were collected and filed from January 2020 to December 2022. A total of 120 patients with chronic obstructive pulmonary disease (COPD) admitted to the hospital were included. The included subjects were standardized and grouped based on the "random number table" method. They were divided into a control group with 60 patients receiving conventional drug treatment and an observation group with 60 patients receiving conventional drug treatment and citalopram; Observe and compare the levels of anxiety and depression, sleep quality, perceived stress levels, treatment compliance, and quality of life between the two groups. After the intervention, the SAS and SDS scores of both groups decreased, with the observation group having a lower score (P<0.05); After intervention, the PSQI and CPSS scores of both groups decreased, and the observation group was significantly lower (P<0.05); The treatment compliance rate in the observation group was 95.00%, significantly higher than the 80.00% in the control group (P<0.05); After intervention, the SF-36 scores of both groups significantly increased, with the observation group being relatively higher (P<0.05). Conclusion: The combination of citalopram in the treatment of patients with chronic obstructive pulmonary disease can significantly improve their anxiety and depression levels, mobilize their treatment confidence, reduce psychological pressure, strengthen compliance, and comprehensively improve their quality of life.

Keywords: citalopram; Chronic obstructive pulmonary disease; Negative emotions; Quality of Life